Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alessandro Crocoli is active.

Publication


Featured researches published by Alessandro Crocoli.


The Journal of Pediatrics | 2011

Symptomatic vocal cord paresis/paralysis in infants operated on for esophageal atresia and/or tracheo-esophageal fistula

Francesco Morini; Barbara Daniela Iacobelli; Alessandro Crocoli; Sergio Bottero; Marilena Trozzi; Andrea Conforti; Pietro Bagolan

OBJECTIVES To describe the prevalence and pathogenesis of symptomatic vocal cord paresis/paralysis (VCP) in patients treated for esophageal atresia (EA), tracheo-esophageal fistula (TEF) or both. STUDY DESIGN Retrospective study of all patients treated for EA/TEF in our center (1995 to 2009). Patients with and without symptomatic VCP were compared for gestational age, birth weight, associated anomalies, referrals, long-gap EA (> 3 cm or 3 vertebral bodies), cervical esophagostomy, anastomotic leakage, length of ventilation, and major cardiac surgery. Prevalence or median (IQR) is reported. RESULTS Of 174 patients, 7 (4%) had symptomatic VCP. Prevalence of referrals (5/7 versus 21/167; P = .0009), long gap (5/7 versus 41/167; P = .0146), previous cervical esophagostomy (5/7 versus 7/167; P < .0001), and anastomotic leakage (3/7 versus 10/167; P = .0097) was higher, and ventilation longer (8.5 days [7.0 to 15.5] versus 6.0 days (5.0 to 7.0); P = .0072) in patients with VCP. CONCLUSIONS In infants treated for EA/TEF, VCP should be ruled out in case of persistent respiratory morbidity or, when present, cautiously monitored. Surgical risk factors should be actively controlled. Further studies are needed to define the prevalence of acquired and congenital VCP in patients with EA/TEF.


Cancer | 2013

Synchronous Bilateral Wilms Tumor A Report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)

Paolo Indolfi; Alessandro Jenkner; Monica Terenziani; Alessandro Crocoli; Annalisa Serra; Paola Collini; Davide Biasoni; Lorenza Gandola; Gianni Bisogno; Giovanni Cecchetto; Martina Di Martino; Paolo D'Angelo; M. Bianchi; Massimo Conte; Alessandro Inserra; Andrea Pession; Filippo Spreafico

The optimal management of bilateral Wilms tumor (BWT) is challenging, and their survival is lower than for unilateral tumors. This report discusses a large series of BWTs treated in Italy in the last 2 decades.


Pediatric Blood & Cancer | 2016

Mediastinal Germ Cell Tumors in Pediatric Patients: A Report From the Italian Association of Pediatric Hematology and Oncology.

Maria Debora De Pasquale; Alessandro Crocoli; Massimo Conte; Paolo Indolfi; Paolo D'Angelo; Renata Boldrini; Monica Terenziani; Alessandro Inserra

Primary mediastinal germ cell tumors (GCTs) are rare in children and still represent a challenge for both adult and pediatric oncologists because of their worse outcome compared to their gonadal counterpart.


Journal of Vascular Access | 2015

Central venous access devices in pediatric malignancies: a position paper of Italian Association of Pediatric Hematology and Oncology

Alessandro Crocoli; Assunta Tornesello; Mauro Pittiruti; Angelica Barone; Paola Muggeo; Alessandro Inserra; Angelo Claudio Molinari; Valeria Grillenzoni; Viviana Durante; Maria Pia Cicalese; Giulio Andrea Zanazzo; Simone Cesaro

Introduction Treatment of pediatric malignancies is becoming progressively more complex, implying the adoption of multimodal therapies. A reliable, long-lasting venous access represents one of the critical requirements for the success of those treatments. Recent technical innovations—such as minimally invasive procedures for placement, new devices and novel materials—have rapidly spread for clinical use in adult patients, but are still not consistently used in the pediatric population. Methods The Supportive Therapy Working Group of Italian Association of Hematology and Oncology (AIEOP) reviewed medical literature focusing on new aspects of central venous access devices (VADs) in pediatric patients affected by oncohematological diseases. Results Appropriate recommendations for clinical use in these patients have been discussed and formulated. Conclusions The importance of the correct choice, management and use of VADs in pediatric oncohematological patients is a necessary prerequisite for an adequate standard of care, also considering the increased chances of cure and the longer life expectancy of those patients with modern therapies.


Annals of Hematology | 2015

Recommendations for the use of long-term central venous catheter (CVC) in children with hemato-oncological disorders: management of CVC-related occlusion and CVC-related thrombosis. On behalf of the coagulation defects working group and the supportive therapy working group of the Italian Association of Pediatric Hematology and Oncology (AIEOP)

Paola Giordano; Paola Saracco; Massimo Grassi; Matteo Luciani; Laura Banov; Francesca Carraro; Alessandro Crocoli; Simone Cesaro; Giulio Andrea Zanazzo; Angelo Claudio Molinari

Central venous catheters (CVC), used for the management of children with hemato-oncological disorders, are burdened by a significant incidence of mechanical, infective, or thrombotic complications. These complications favor an increasing risk in prolongation of hospitalization, extra costs of care, and sometimes severe life-threatening events. No guidelines for the management of CVC-related occlusion and CVC-related thrombosis are available for children. To this aim, members of the coagulation defects working group and the supportive therapy working group of the Italian Association of Pediatric Hematology and Oncology (AIEOP) reviewed the pediatric and adult literature to propose the first recommendations for the management of CVC-related occlusion and CVC-related thrombosis in children with hemato-oncological disorders.


Journal of Pediatric Surgery | 2012

Congenital Askin tumor with favorable outcome: case report and review of the literature ☆

Alessandro Crocoli; Pietro Bagolan; Renata Boldrini; Gian Luigi Natali; Maria Antonietta De Ioris; Francesco Morini

Several disorders may present as cystic complex lesions of the fetal thorax, both with benign and malignant behavior. As a consequence, their detection may pose diagnostic, therapeutic, and parental counseling dilemmas. We describe a neonate with a congenital Askin tumor, diagnosed at the 37th week of gestation and treated after birth. Counseling and treatment challenges are discussed.


BMC Cancer | 2018

Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma

Virginia Di Paolo; Ida Russo; Renata Boldrini; Lucilla Ravà; Marco Pezzullo; Maria Chiara Benedetti; Angela Galardi; Marta Colletti; Rossella Rota; Domenico Orlando; Alessandro Crocoli; Héctor Peinado; Giuseppe Maria Milano; Angela Di Giannatale

BackgroundThe Intratumoral Microvessel Density (IMVD) is commonly used to quantify tumoral vascularization and is usually assessed by pan-endothelial markers, such as CD31. Endoglin (CD105) is a protein predominantly expressed in proliferating endothelium and the IMVD determined by this marker measures specifically the neovascularization. In this study, we investigated the CD105 expression in pediatric rhabdomyosarcoma and assessed the neovascularization by using the angiogenic ratio IMVD-CD105 to IMVD-CD31.MethodsParaffin-embedded archival tumor specimens were selected from 65 pediatric patients affected by rhabdomyosarcoma. The expression levels of CD105, CD31 and Vascular Endothelial Growth Factor (VEGF) were investigated in 30 cases (18 embryonal and 12 alveolar) available for this study. The IMVD-CD105 to IMVD-CD31 expression ratio was correlated with clinical and pathologic features of these patients.ResultsWe found a specific expression of endoglin (CD105) in endothelial cells of all the rhabdomyosarcoma specimens analyzed. We observed a significant positive correlation between the IMVD individually measured by CD105 and CD31. The CD105/CD31 expression ratio was significantly higher in patients with lower survival and embryonal histology. Indeed, patients with a CD105/CD31 expression ratio < 1.3 had a significantly increased OS (88%, 95%CI, 60%–97%) compared to patients with higher values (40%, 95%CI, 12%–67%). We did not find any statistical correlation among VEGF and EFS, OS and CD105/CD31 expression ratio.ConclusionCD105 is expressed on endothelial cells of rhabdomyosarcoma and represent a useful tool to quantify neovascularization in this tumor. If confirmed by further studies, these results will indicate that CD105 is a potential target for combined therapies in rhabdomyosarcoma.


Pediatric Blood & Cancer | 2017

Comparative retrospective study on the modalities of biopsying peripheral neuroblastic tumors: a report from the Italian Pediatric Surgical Oncology Group (GICOP)

Stefano Avanzini; Maria Grazia Faticato; Alessandro Crocoli; Calogero Virgone; Camilla Viglio; Elisa Severi; Anna Maria Fagnani; Giovanni Cecchetto; Giovanna Riccipetitoni; Bruno Noccioli; Ernesto Leva; Angela Rita Sementa; Girolamo Mattioli; Alessandro Inserra

Peripheral neuroblastic tumors are the most common extracranial solid neoplasms in children. Early and adequate tissue sampling may speed up the diagnostic process and ensure a prompt start of optimal treatment whenever needed. Different biopsy techniques have been described. The purpose of this multi‐center study is to evaluate the accuracy and safety of the various examined techniques and to determine whether a preferential procedure exists.


Seminars in Pediatric Surgery | 2016

Palliative care and pediatric surgical oncology

Alessandro Inserra; Alessandra Narciso; Guglielmo Paolantonio; Raffaella Messina; Alessandro Crocoli

Survival rate for childhood cancer has increased in recent years, reaching as high as 70% in developed countries compared with 54% for all cancers diagnosed in the 1980s. In the remaining 30%, progression or metastatic disease leads to death and in this framework palliative care has an outstanding role though not well settled in all its facets. In this landscape, surgery has a supportive actor role integrated with other welfare aspects from which are not severable. The definition of surgical palliation has moved from the ancient definition of noncurative surgery to a group of practices performed not to cure but to alleviate an organ dysfunction offering the best quality of life possible in all the aspects of life (pain, dysfunctions, caregivers, psychosocial, etc.). To emphasize this aspect a more modern definition has been introduced: palliative therapy in whose context is comprised not only the care assistance but also the plans of care since the onset of illness, teaching the matter to surgeons in training and share paths. Literature is very poor regarding surgical aspects specifically dedicated and all researches (PubMed, Google Scholar, and Cochrane) with various meshing terms result in a more oncologic and psychosocial effort.


Journal of Vascular Access | 2014

A dedicated protocol and environment for central venous catheter removal in pediatric patients affected by onco-hematological diseases

Alessandro Crocoli; Cristina Martucci; Mariangela Padua; Annalisa Serra; Antonella Cacchione; Valentina Coletti; Giuseppe Palumbo; Marta Luisa Ciofi degli Atti; Lucilla Ravà; Alessandro Inserra

Purpose The removal of long-term central venous catheters (CVCs) is not performed according to evidence-based guidelines, thus conveying the message that it is a procedure of secondary importance. Our study aims at comparing the experience at Bambino Gesù Pediatric Hospital before and after the implementation of a dedicated protocol and the identification of a specific area to perform such a procedure under the so-called nonoperating room anesthesia (NORA). Methods Starting on January 1, 2010, an appropriate protocol regarding long-term CVC removal was applied. Then, data from all patients who underwent CVC removal under NORA regimen were compared with patients who have undergone the same procedure before the beginning of such protocol in terms of complication rate, duration of procedure, and costs. Results Between January 2010 and December 2012, 266 patients were evaluated for long-term CVC removal under a NORA regimen. Of these, 194 underwent the procedure. In the period from January 2007 to December 2009, 60 out of 82 patients scheduled for elective removal of long-term CVC in the operating theatre were eligible for this study. Median procedure time was 7 min for removal in NORA and 10 min for the operating theatre (p=0.016); no complications occurred. Conclusion Long-term CVC removal is an often-neglected procedure, carrying a small, but definite rate of complications. Our study shows that CVC removal performed in NORA regimen is safe and feasible, also allowing multiple procedures in the same session with prompt management of possible complications and reduction of the anxiety and pain associated with the procedure.

Collaboration


Dive into the Alessandro Crocoli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Renata Boldrini

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aurora Castellano

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chiara Grimaldi

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Annalisa Serra

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Gian Luigi Natali

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge